CIPLA

March 19 (Reuters) - Cipla Ltd CIPL.NS:

• CIPLA - APPROVED INVESTMENT UPTO USD 100 MILLION IN EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED

• CIPLA- APPROVED INVESTMENT UPTO USD 100 MILLION IN THE EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED

• CIPLA - DESIGNATES P R RAMESH AS VICE-CHAIRMAN EFFECTIVE 1 APRIL 2026

• CIPLA - APPROVES SCHEME OF AMALGAMATION OF INZPERA HEALTHSCIENCES LIMITED WITH CIPLA

Source text: ID:nNSE8YvWkL

Further company coverage: CIPL.NS

(([email protected];))

March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O:

• FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION

• FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING GENERIC SODIUM THIOSULFATE UNTIL SEPTEMBER 1, 2033

• FENNEC PHARMACEUTICALS INC: UNDER TERMS OF SETTLEMENT, LAWSUIT WILL BE DISMISSED WITH EACH PARTY BEARING THEIR OWN COSTS

Source text: ID:nGNX9TGBKl

Further company coverage: FENC.O

(([email protected];))

Changes dateline, updates with CSL's expansion

March 9 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing.

Roche ROG.S

The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.

The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)

(([email protected];))

By Jennifer Rigby

LONDON, March 5 (Reuters) - South Africa is asking local drugmakers to start a process to make Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where it is most needed.

The government is working alongside international partners, including Unitaid and the United States Pharmacopoeia, to identify which local company could make the twice-yearly injection safely, effectively and affordably, and provide any support needed. They will then recommend that company to Gilead.

Gilead, a U.S. pharmaceutical company, granted six voluntary licences in 2024 to generic manufacturers across India, Egypt and Pakistan to produce and supply the drug to 120 low- and middle-income countries. These included South Africa, although there was criticism that no South African drugmakers were included.

A licence for a South African company would be the seventh such deal, potentially boosting access to a drug many HIV/AIDS experts have said could help bring an end to the 44-year-old pandemic by slashing the numbers of new infections.

Gilead said it has been open to adding an additional voluntary license for local manufacturing in Sub-Saharan Africa. "Gilead will review the proposals and assess whether required quality standards can be met before any voluntary license is granted," the company said in an email.

AFRICA REMAINS EPICENTRE OF HIV PANDEMIC

Despite progress, the African region remains the epicentre of the HIV pandemic. South Africa has the highest number of people affected at 8 million – around one in five adults – living with the virus. Several companies in South Africa already make HIV treatments or sterile injectables, like Aspen Pharmacare.

Paul Mashatile, chair of the South African National AIDS Council and deputy president, said making the drug in South Africa would benefit the whole region.

“Africa can no longer rely on medicines produced elsewhere for diseases that affect us most,” said Kenyan President William Ruto, African Union lead on local manufacturing of health commodities.

ACCESS CHALLENGES

In the past, low- and middle-income countries waited years for HIV drugs available in richer nations. Lenacapavir is already available in some African countries through an initiative supported by The Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government, but demand is expected to outstrip supply until the generic manufacturers start making the drug.

Those agreements also faced some criticism for excluding middle-income countries like Brazil. A South African company could try to expand access there, too, Unitaid said.

“It’s an opportunity to open the door further,” said Unitaid’s director of program, Robert Matiru, although he said a licence for a South African company was the key aim.

(Reporting by Jennifer Rigby, additional reporting by Nellie Peyton and Nqobile Dludla in Johannesburg and Deena Beasley in Los Angeles; Editing by Kirsten Donovan)

(([email protected]))

March 2 (Reuters) - Cipla Ltd CIPL.NS:

• INCORPORATED SUBSIDIARY CIPLA MIDDLE EAST COMPANY IN KINGDOM OF SAUDI ARABIA

Source text: ID:nnAZN4SJ5GY

Further company coverage: CIPL.NS

(([email protected];;))

Feb 27 (Reuters) - Cipla Ltd CIPL.NS:

• CIPLA STRENGTHENS US PORTFOLIO WITH THE LAUNCH OF GENERIC SAXENDA® (LIRAGLUTIDE INJECTION) FOR WEIGHT MANAGEMENT THERAPY

• CIPLA: TO LAUNCH GENERIC SAXENDA ON AN IMMEDIATE BASIS

Source text: ID:nPn2VJ63Sa

Further company coverage: CIPL.NS

(([email protected];))

** India's Cipla CIPL.NS drops ~2% to 1,320 rupees, top loser on pharma index .NIPHARM, which is up 0.4%

** U.S. FDA concluded inspection at a facility of Pharmathen, Cipla's exclusive contract manufacturer for its key tumour therapy Lanreotide, indicating it as "official action indicated"

** Classification means regulatory or administrative actions are recommended - regulator's website

** Greece-based Pharmathen had temporarily paused production in Q3 to work through FDA remediation requirements, resulting in CIPL missing results estimates

** Avg rating on CIPL at "hold"; median PT is 1,445 rupees - data compiled by LSEG

** YTD, stock down 12.2% vs pharma index's 0.8% drop

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Feb 20 (Reuters) - Cipla Ltd CIPL.NS:

• LIC RAISES STAKE IN CIPLA TO 9.091% FROM 7.055% BETWEEN NOV AND FEB- FILING

Source text: ID:nBSE3SBW2S

Further company coverage: CIPL.NS

(([email protected];))

Adds executive's complete designation in paragraph 4

By Rishika Sadam and Kashish Tandon

HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly LLY.N wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contract manufacturing in the country.

Sales of the blockbuster weight-loss drug doubled within months of its launch in the South Asian country and became its top-selling medicine by value, underscoring the growing popularity of obesity treatments in a country projected to have the world's second-largest obese population by 2050.

The company, which does not currently operate its own manufacturing facility in India, plans to export locally produced drugs to markets across the world as part of its broader supply network, drawing on the country's robust contract manufacturing setup.

"We are actually looking at India to be a hub, part of our global supply chain, and therefore supplying the world," Winselow Tucker, president and general manager, Eli Lilly and Company (India), told Reuters on the sidelines of the BioAsia conference in Hyderabad.

"We will continue to look at that (investment) and scale that over time," Tucker said, declining to name contract manufacturers or discuss plans for a dedicated plant.

The company also plans to bring additional products to India, including its Alzheimer's drug donanemab and potential future obesity treatments such as its experimental oral weight-loss drug orforglipron, pending regulatory approvals, Tucker said.

PRICE RACE

In India, Lilly competes with Danish drugmaker Novo Nordisk NOVOb.CO, which makes Wegovy.

The world's most populous nation is set for a weight-loss drug boom this year as local firms race to launch cheaper, generic versions of Wegovy after Novo's patent on semaglutide expires in India next month.

Novo cut Wegovy's price by up to 37% last year to defend market share.

Tucker dismissed concerns about Mounjaro facing similar pressure, saying the drug's composition offered superior efficacy and would keep it competitive.

"We have priced it (Mounjaro) for value, and we believe it is priced appropriately," Tucker said.

Lilly is instead focused on boosting digital and social media campaigns to raise obesity awareness and expand Mounjaro's reach in smaller Indian cities. It has widened its distribution beyond major metros through partnerships, such as with Indian drugmaker Cipla CIPL.NS and with digital health platforms Tata 1MG, Practo and Apollo.

(Reporting by Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Dhanya Skariachan and Janane Venkatraman)

(([email protected]; 8800437922;))

Repeats story from 13th Feburary with no changes to text

By Rishika Sadam

Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.

Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.

It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.

The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.

"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.

In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.

The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.

Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.

India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.

(Reporting by Rishika Sadam; Editing by Tasim Zahid)

(([email protected];))

By Rishika Sadam

Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.

Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.

It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.

The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.

"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.

In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.

The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.

Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.

India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.

(Reporting by Rishika Sadam; Editing by Tasim Zahid)

(([email protected];))

Feb 10 (Reuters) - Cipla Ltd CIPL.NS:

• CIPLA - USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN HAUPPAUGE, LONG ISLAND, NEW YORK, USA

• CIPLA - ON CONCLUSION OF INSPECTION, INVAGEN HAS RECEIVED 2 INSPECTIONAL OBSERVATIONS

Source text: ID:nNSEb8YkN0

Further company coverage: CIPL.NS

(([email protected];))

Feb 5 (Reuters) - Cipla Ltd CIPL.NS:

• CIPLA - TAX DEPARTMENT INITIATES INSPECTION AT CIPLA FACILITIES

• CIPLA - INSPECTION HAS NO FINANCIAL IMPACT ON CIPLA

Source text: ID:nNSE88rNT2

Further company coverage: CIPL.NS

(([email protected];))

Changes dateline, adds Eli Lilly details in paragraph 11

Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.

Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April last year it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed and Maju Samuel)

(([email protected];))

** Shares of Cipla CIPL.NS fall 1.1% to 1,300 rupees, lowest since January 2024

** JP Morgan downgrades India's No.3 drugmaker to "Neutral" with PT of 1,460 rupees after it reported disappointing Q3 results

** Brokerage says co's Q3 revenue was 5% below JPM's estimate, mainly due to sharp decline in US sales and weaker African market growth

** Co's U.S. revenue fell 26% year-on-year due to sharp decline in sales of its generic version of Bristol-Myers Squibb's BMY.N cancer drug Revlimid due to its imminent patent expiry and a month long supply chain disruption on key tumour therapy Lanreotide - note

** Brokerage says while Cipla's pipeline offers long-term promise with four respiratory and four peptide assets, it sees material contribution starting only from FY28

** Stock fell 0.96% in 2025

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

Jan 23 (Reuters) - Cipla CIPL.NS, India's third-largest drugmaker by revenue, reported quarterly profit below estimates on Friday, dragged by a production halt at the exclusive manufacturer of its no. 2 revenue contributor tumour drug Lanreotide.

The company, which makes the popular Asthalin inhaler and the Cofsils cough drops, reported consolidated net profit slumped 57% to 6.76 billion rupees ($73.8 million) for the quarter ended December 31 from 15.71 billion rupees a year earlier.

Analysts, on average, had expected 12.42 billion rupees, as per data compiled by LSEG.

($1 = 91.6200 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)

(([email protected]; 8800437922;))

Adds details on Roche, Abbvie and CSL

Jan 20 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April last year it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.

It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.

It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

CSL CSL.AX

Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Maju Samuel, Tasim Zahid and Sahal Muhammed)

(([email protected];))

** Drugmaker Cipla's CIPL.NS stock falls as much as 4.7% to 1,367.20 rupees, lowest level since April 2025

** Last down 2.4%, top loser on Nifty 50 .NSEI, which is up 0.77%

** Tumour drug Lanreotide supply hit after partner Pharmathen's production pause; drug is major rev source for CIPL in U.S.

** Nuvama downgrades to "reduce" from "hold", cuts PT to 1,360 rupees from 1,715 rupees; says pause brings uncertainty for FY27E

** BofA Securities cuts PT to 1,420 rupees from 1,500 rupees; says co's near-term earnings, news flow could weigh on stock

** Morgan Stanley says pause creates U.S. revenue overhang; stock to underperform over next 30 days

** CIPL rated "buy" on avg by 36 analysts, median PT 1,675 rupees - LSEG data

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Changes dateline, paragraph 1 and updates AbbVie

Jan 13 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers imposing a 100% tariff on imported branded and patented medicines.

Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.

Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.

It will also invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

U.S. drugmaker AbbVie ABBV.N has committed $100 billion over the next decade to U.S.-based research and development, expanding direct-to-patient access through TrumpRx for widely prescribed medications including Alphagan, Combigan, Humira, and Synthroid

In exchange, AbbVie will receive exemptions from tariffs and future pricing mandates, though additional terms of the agreement with the Trump's administration remain confidential.

Before this, AbbVie confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

CSL CSL.AX

Australia's CSL said it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the North American country over the next five years.

(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh and Sneha S K in Bengaluru; Editing by Devika Syamnath, Leroy Leo, Vijay Kishore, Sahal Muhammed, Maju Samuel and Tasim Zahid)

(([email protected];))

Jan 7 (Reuters) - Cipla Ltd CIPL.NS:

• CLARIFIES ON REPORT USFDA ISSUES FORM 483 OBSERVATIONS ON PHARMATHEN

• PHARMATHEN MANUFACTURES LANREOTIDE INJECTION FOR CIPLA USA

• PHARMATHEN IS OUR SUPPLY PARTNER, MANUFACTURING LANREOTIDE INJECTION FOR CIPLA USA INC

• PHARMATHEN RECEIVED NINE INSPECTIONAL OBSERVATIONS FROM USFDA

Source text: ID:nBSE2qbc0D

Further company coverage: CIPL.NS

(([email protected];))

** Cipla CIPL.NS drops ~2% to 1,514.30 rupees; had lost 2.6% in last session

** On analyst call, India's no. 3 drugmaker lowers FY26 EBITDA margin outlook, citing declining contribution from generic Revlimid, higher R&D costs

** CLSA sees tepid H2 for co, almost negligible contribution from gRevlimid

** On Thursday, Cipla beat Q2 profit view, announced CEO rejig

** Stock rated "buy" on avg; median PT is 1,720 rupees, per data compiled by LSEG

** YTD, CIPL gains 0.9%

(Reporting by Kashish Tandon)

(([email protected]; +91 8800437922))

Adds details from media call, analyst comment

By Rishika Sadam and Kashish Tandon

Oct 30 (Reuters) - Cipla's CIPL.NS global chief executive and managing director, Umang Vohra, will step down at the end of March after almost a decade in the top role, the Indian drugmaker said on Thursday.

Achin Gupta, the firm's global chief operating officer, will take over from April 1, 2026 for five years, the company said.

Gupta joined Cipla in 2021 and has been in his current role since February. He was the CEO of Cipla's India business, its biggest, and expanded the company's chronic therapy drugs.

"I think Gupta's strength...lies in licensing and M&A and with Cipla now having good cash, we expect he would leverage that experience to put the cash to use," Vishal Manchanda from Systematix Institutional Equities said.

Vohra told reporters that "if there is a requirement of the board, then obviously, I'm happy to help in whatever form," but refused to share his plan after he steps down.

NEW STRATEGY FOR CIPLA

There will be "shades of a new" strategy with the new management given the geopolitical sensitivity in some markets, Vohra said, adding that Cipla must become an innovation player over the next five-to-seven years.

"I think there will be more investments in that," he said.

The firm, India's third-largest drugmaker by sales, beat quarterly profit estimates on Thursday, driven by strong local demand for its urology, diabetes and cardiac therapy drugs.

Its consolidated net profit rose 3.7% to 13.51 billion rupees ($153.7 million) in the quarter ended September 30, beating analysts' estimates of 13.47 billion rupees, per data compiled by LSEG.

Total revenue grew 7.6% to 75.89 billion rupees, slightly above expectations of 74.30 billion rupees, helped by a 7% growth in the India market revenue.

Sales in North America stood at $233 million, down from $237 million in the year-ago period.

The company said it expects to launch four major respiratory drugs in the U.S. by the end of 2026, and three peptide-related drugs, which are mostly used for weight-loss treatment.

(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee)

(([email protected];))

** Shares of Eli Lilly LLY.N rises to 0.73% to $817.82 on Thursday after it signed a distribution agreement with Indian drugmaker Cipla CIPL.NS to sell weight-loss drugs in the country

** LLY is on track for second straight session of gains and is set for highest close in one week

** Under the agreement, LLY will manufacture the drug and Cipla will market it under the brand name Yurpeak, the drugmakers said

** Yurpeak will be available as a once-weekly pre-filled injector pen, same as Lilly's Mounjaro Kwikpen, allowing healthcare providers to personalise treatment plans to individual patient needs

** Among 32 analysts covering LLY, avg rating is "BUY" and median PT is $900

** LLY is up 6% YTD versus ~6% gain in the S&P 500 health index .SPXHC

(Reporting by Chibuike Oguh in New York)

((Email: [email protected]; Phone: +332-219-1834; Reuters Messaging: [email protected]))

Adds Pfizer investment plan in paragraph 5

Oct 1 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration moves ahead with a 100% tariff on imported branded and patented drugs, starting October 1.

The sweeping measure has triggered a flurry of activity across the industry, including fast-tracking U.S. manufacturing projects, price cuts and direct-to-consumer sales.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Pfizer PFE.N

Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath, Leroy Leo and Vijay Kishore)

(([email protected];))

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2.6% on Friday after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1.

All 20 constituents of the index were lower as of 9:30 a.m. IST. Heavyweight Sun Pharmaceutical Industries SUN.NS fell 3.4%.

The U.S. takes slightly more than a third of India’s drug exports, mostly cheaper generics, which rose 20% to about $10.5 billion in fiscal 2025.

The near term impact of the tariffs is likely to be limited, as India mainly exports generics, ICICI Securities research analyst Pankaj Pandey said in a note.

"That being said, uncertainty still remains whether complex generics and biosimilars will come under tariff embargo in the future," Pandey added.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected];))

Updates with GSK's investment plan

Sept 17 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.

However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

GSK GSK.L

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

Eli Lilly LLY.N

The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia. The facility is the first of four new U.S. plants planned under its $27 billion expansion over the next five years.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

Pfizer PFE.N

Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)

(([email protected];))

Sept 3 (Reuters) - Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%.

But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.

Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:

Eli Lilly LLY.N

The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.

Johnson & Johnson JNJ.N

The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.

Locations for the other plants remain undisclosed.

Roche ROG.S

The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years.

A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.

Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.

CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs.

AstraZeneca AZN.L

The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.

It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."

Novartis NOVN.S

The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.

Sanofi SASY.PA

The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.

Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.

Biogen BIIB.O

The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.

Merck MRK.N

The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March.

Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.

CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.

Amgen AMGN.O

The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.

Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.

Pfizer PFE.N

Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed.

Novo Nordisk NOVOb.CO

The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".

AbbVie ABBV.N

The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade.

It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.

Gilead Sciences GILD.O

Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.

Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.

Cipla CIPL.NS

The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York.

(Reporting by Siddhi Mahatole, Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Leroy Leo)

(([email protected];))

Aug 26 (Reuters) - Cipla Ltd CIPL.NS:

• CIPLA LTD - COMPLETES ACQUISITION OF 20% VOTING RIGHTS IN ICALTECH

Source text: ID:nBSEcdQWyK

Further company coverage: CIPL.NS

(([email protected];;))